Hope Liou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hope Liou has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Noel Andrew Warfel
University of Arizona College of Medicine 3 Department of Cellular & Molecular Medicine Tucson, AZ 85721
22 shared publications - Amber N. Clements
Cancer Biology Graduate Program, University of Arizona, Tucson, Arizona
21 shared publications - Andrea L. Casillas
Cancer Biology Graduate Program, University of Arizona, Tucson, Arizona
21 shared publications - Anne E. Cress
The University of Arizona Comprehensive Cancer Center, Tucson, Arizona; Department of Cellular and Molecular Medicine, College of Medicine, University of Arizona, Tucson, Arizona
21 shared publications - Caitlyn E. Flores
Cancer Biology Graduate Program, University of Arizona, Tucson, AZ, USA
21 shared publications - Shailender Singh Chauhan
University of Arizona Cancer Center, Tucson, Arizona
21 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- Open Access
- 22 May 2026
- Published by Elsevier in Cancer Letters
- Vol. 654, 218611
Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress
- 22 May 2026
- Published by Elsevier in Cancer Letters
- Vol. 654, 218611
Open AccessKinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress